Duality Biologics

Private

Biotechnology company specializing in antibody-drug conjugate (ADC) technology for oncology. Entered a $1B collaboration with Genentech to develop next-generation ADCs targeting drug-resistance mechanisms in cancer.

Company Info

Sector:Antibody-Drug Conjugates

Headquarters:China

Founded:2019

Website:www.dualitybiologics.com/

Upcoming Milestones & Key Dates

2026

Partnership

Genentech $1B collaboration initiation

Clinical Development Pipeline

ADC platform candidates

Target: Various tumor antigens

Drug-resistant cancers

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Careers & Job Openings

See all open roles

Apply Now →